LeMaitre Vascular (NASDAQ:LMAT) Share Price Passes Above 200 Day Moving Average – Should You Sell?

LeMaitre Vascular, Inc. (NASDAQ:LMAT)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $98.26 and traded as high as $100.85. LeMaitre Vascular shares last traded at $99.79, with a volume of 224,599 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on LMAT shares. Citizens Jmp upped their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Weiss Ratings lowered LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Barrington Research reaffirmed an “outperform” rating and issued a $120.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Wells Fargo & Company increased their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $112.60.

LeMaitre Vascular Trading Up 2.0%

The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The company’s fifty day moving average is $97.22 and its 200-day moving average is $98.26. The firm has a market capitalization of $2.28 billion, a P/E ratio of 36.82, a P/E/G ratio of 2.72 and a beta of 0.52.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. The business had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. LeMaitre Vascular’s revenue was up 11.1% compared to the same quarter last year. During the same period last year, the business posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st were given a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 36.90%.

Insider Transactions at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 5,044 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the transaction, the director owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. The trade was a 56.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Trent G. Kamke sold 2,928 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the sale, the insider owned 3,749 shares of the company’s stock, valued at approximately $401,143. The trade was a 43.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 54,453 shares of company stock worth $5,906,174. Company insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds have recently modified their holdings of the business. Royal Bank of Canada raised its stake in LeMaitre Vascular by 1.5% during the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock valued at $9,579,000 after purchasing an additional 1,735 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 36.4% during the 1st quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock worth $2,339,000 after purchasing an additional 7,445 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of LeMaitre Vascular by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after buying an additional 539 shares during the last quarter. Millennium Management LLC raised its position in shares of LeMaitre Vascular by 119.8% during the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after buying an additional 115,141 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after buying an additional 55,804 shares during the period. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.